Effect of palivizumab on respiratory syncytial virus-associated burden of disease: a randomised controlled trial

Trial Profile

Effect of palivizumab on respiratory syncytial virus-associated burden of disease: a randomised controlled trial

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections; Wheezing
  • Focus Therapeutic Use
  • Acronyms MAKI
  • Most Recent Events

    • 09 May 2013 Status changed from recruiting to completed.
    • 09 May 2013 Results published in the New England Journal of Medicine.
    • 01 Nov 2012 Ethical considerations and rationale published in Contemporary Clinical Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top